News Image

Don't overlook NASDAQ:SNY—it's a hidden gem with strong fundamentals and an attractive price tag.

By Mill Chart

Last update: Dec 6, 2023

Uncover the potential of SANOFI-ADR (NASDAQ:SNY) as our stock screener's choice for an undervalued stock. NASDAQ:SNY maintains a strong financial position and offers an appealing valuation. We'll delve into the specifics below.

Understanding NASDAQ:SNY's Valuation

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NASDAQ:SNY scores a 8 out of 10:

  • SNY is valuated reasonably with a Price/Earnings ratio of 10.12.
  • Based on the Price/Earnings ratio, SNY is valued cheaply inside the industry as 89.22% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 24.81. SNY is valued rather cheaply when compared to this.
  • SNY is valuated reasonably with a Price/Forward Earnings ratio of 9.60.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SNY indicates a rather cheap valuation: SNY is cheaper than 88.73% of the companies listed in the same industry.
  • SNY's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 19.91.
  • SNY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. SNY is cheaper than 95.10% of the companies in the same industry.
  • SNY's Price/Free Cash Flow ratio is rather cheap when compared to the industry. SNY is cheaper than 88.73% of the companies in the same industry.
  • The excellent profitability rating of SNY may justify a higher PE ratio.

Evaluating Profitability: NASDAQ:SNY

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:SNY has achieved a 8:

  • Looking at the Return On Assets, with a value of 10.12%, SNY belongs to the top of the industry, outperforming 93.14% of the companies in the same industry.
  • The Return On Equity of SNY (17.47%) is better than 91.18% of its industry peers.
  • SNY has a Return On Invested Capital of 15.53%. This is amongst the best in the industry. SNY outperforms 92.16% of its industry peers.
  • The 3 year average ROIC (6.95%) for SNY is below the current ROIC(15.53%), indicating increased profibility in the last year.
  • Looking at the Profit Margin, with a value of 18.09%, SNY belongs to the top of the industry, outperforming 93.14% of the companies in the same industry.
  • SNY has a better Operating Margin (27.75%) than 94.12% of its industry peers.
  • In the last couple of years the Operating Margin of SNY has grown nicely.
  • SNY has a better Gross Margin (70.31%) than 78.43% of its industry peers.

Deciphering NASDAQ:SNY's Health Rating

A critical element of ChartMill's stock evaluation is the Health Rating, which spans from 0 to 10. This rating considers multiple health factors, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:SNY has received a 7 out of 10:

  • SNY has an Altman-Z score of 3.08. This indicates that SNY is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of SNY (3.08) is better than 76.47% of its industry peers.
  • The Debt to FCF ratio of SNY is 2.59, which is a good value as it means it would take SNY, 2.59 years of fcf income to pay off all of its debts.
  • SNY has a Debt to FCF ratio of 2.59. This is amongst the best in the industry. SNY outperforms 90.69% of its industry peers.
  • SNY has a Debt/Equity ratio of 0.22. This is a healthy value indicating a solid balance between debt and equity.
  • SNY does not score too well on the current and quick ratio evaluation. However, as it has excellent solvency and profitability, these ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.

ChartMill's Evaluation of Growth

ChartMill assigns a proprietary Growth Rating to each stock. The score is computed by evaluating various growth aspects, like EPS and revenue growth. We take into account the history as well as the estimated future numbers. NASDAQ:SNY was assigned a score of 5 for growth:

  • The Earnings Per Share has grown by an nice 17.29% over the past year.
  • The Earnings Per Share has been growing by 8.29% on average over the past years. This is quite good.
  • SNY shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.47%.

Our Decent Value screener lists more Decent Value stocks and is updated daily.

Our latest full fundamental report of SNY contains the most current fundamental analsysis.

Disclaimer

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.

Back

SANOFI-ADR

NASDAQ:SNY (2/16/2024, 7:26:35 PM)

After market: 46.0011 -0.18 (-0.39%)

46.18

-0.21 (-0.45%)

SNY News

News Imagea day ago - The Motley Fool2 Healthcare Stocks You Can Buy and Hold for the Next Decade

Don't count these companies out too soon.

News Imagea day ago - Seeking AlphaSanofi, Regeneron win Japan approval for Dupixent in CSU indication (NASDAQ:REGN)

Sanofi and Regeneron Pharmaceuticals gain approval for their allergy medication Dupixent in Japan, making it the first country to approve the drug for the...

News Image2 days ago - InvestorPlace7 Contrarian Biotech Stocks to Consider Amid Sector Weakness

Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts.

News Image2 days ago - InvestorPlaceThe 3 Biotech Stocks That Could Make Your February Unforgettable

After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks.

News Image3 days ago - ChartmillWhy the dividend investor may take a look at NASDAQ:SNY.

Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics.

News Image3 days ago - ChartmillNASDAQ:SNY is an undervalued gem with solid fundamentals.

SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

News Image9 days ago - Seeking AlphaAstraZeneca stock tumbles despite Q4 beat (NASDAQ:AZN)

AstraZeneca's operating profits fell short of expectations, but its oncology portfolio performed well, leading to a revenue beat in Q4 2023. Read more here.

News Image12 days ago - Investor's Business DailyNovo Nordisk To Up Production Capacity As Parent Buys Catalent

NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash.

News Image16 days ago - The Motley FoolSanofi (SNY) Q4 2023 Earnings Call Transcript

SNY earnings call for the period ending December 31, 2023.

News Image16 days ago - Investor's Business DailySanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't.

The company missed total sales and earnings expectations.

News Image16 days ago - Seeking AlphaSanofi incurs loss in Q4 amid generic competition, currency woes (NASDAQ:SNY)

Sanofi, a French pharmaceutical firm, reports a net loss in Q4 2023 due to currency movements despite strong sales of Dupixent.

SNY Links
Follow us for more